Endocrine Abstracts

Introduction: Type two diabetes is characterized by a chronic metabolic state (obesity, high blood pressure, and dyslipidemia) and insulin resistance. There is insufficient pancreatic insulin production and ineffective use of the produced insulin resulting in abnormally high blood glucose levels (hyperglycaemia). Metabolic syndrome and diabetes are associated with increased cardiovascular risk, reduced life expectancy and a reduction in quality of life. Glucagon-like peptide 1 (GLP-1) receptor agonists are used in type 2 patients whose HbA1c remains uncontrolled despite the use of multiple oral therapies. This audit was designed to evaluate the effect of Semaglutide initiation on HbA1c and weight change in patients from diabetic day centre of our Lady’s hospital Navan. Method Patients with type two diabetes commenced on Semaglutide were identified from their medical notes from the diabetic day centre of OLHN. Patients were commenced on once weekly Semaglutide of 0.5 mg sub cutaneous once weekly and up titrated to a dose of 1mg as tolerated. In total 30 patients were identified and included in this audit. The mean age of participants was 52 years. All patients had in person review prior to commencement to identify them as candidates for treatment and have an objective weight and HbA1c recorded prior to commencement.

Results: 85% patients commenced on Semaglutide achieved the Nice guidelines standard reduction in HbA1c. More than 75% of patients commenced on Semaglutide lost > 5% of their body weight and the remaining had modest weight reduction (< 5%). Conclusion From our snapshot audit we have demonstrated that patients in our hospital demonstrated significant reductions in both HbA1c and/or weight when commenced on either 0.5 or 1 mg of Semaglutide once weekly.